Biotech at an Inflection Point: How AI, Multimodal Models, and New Industry Structures Are Rewiring the Innovation Landscape in 2026

2025, in many ways, wasn’t the typical gradual, incremental trend — more data here, more partnerships there, perhaps a few policy breakthroughs, but rather rapid acceleration of an overall industry step change.

Across healthcare operations, drug discovery, oncology, and the business architecture of the biopharmaceutical industry, we are witnessing a reconfiguration of the innovation ecosystem. Not a shift around the edges — but a reorganization of how and where discovery happens, how AI is embedded into daily workflows, and how data flows across organizational and geographic boundaries.

Multiple independent reports — from McKinsey, Nature, Nature Biotechnology, and Evaluate — converge on the same conclusion:

Biotech is entering a new innovation commons: a distributed, AI-native infrastructure layer that is beginning to democratize discovery, development, and delivery.

Below is a synthesis of how, why, and where this shift is unfolding.

1. AI Adoption Is Not Monolithic — But Healthcare Has Become the System’s Pacemaker

One of the most misquoted figures in the 2025 discourse is McKinsey’s “88% of organizations use AI” statistic.
It is a cross-industry number, not a reflection of healthcare specifically.

What matters more — and what both McKinsey and Evaluate make clear — is the rate at which healthcare is moving.

Venture Capital data shows that healthcare is not merely adopting AI:
it is adopting faster than any other major sector, with 2.2× higher adoption velocity than the broader economy.

But the more important insight is where this adoption is occurring.

Across the healthcare delivery system — not in pharma R&D — we see the steepest uptake:

• $1.4B in healthcare AI spend in 2024–25

• $1B of that driven by provider systems

• 85% of that spend flowing to startups, not incumbents

• 10× YOY growth in prior authorization automation

• 20× YOY in patient engagement and intake

• Ambient clinical AI has become a $600M market almost overnight

Healthcare delivery is now the on-ramp for scaled AI deployment, with hospitals and outpatient groups pulling the industry forward.

In other words:

Pharma built the first wave of ML research. Healthcare providers are now building the first large-scale production systems.

This shift — from R&D-centric AI to operations-centric AI — is reshaping the entire adoption landscape.

2. Scaling AI Requires Rewriting Workflows — Not Just Training Better Models

McKinsey’s 2025 report highlights a structural pattern across industries:

• Adoption is high

• Scaling is low

• The difference lies in workflow redesign

Organizations that succeed at scale are 3.6× more likely to change underlying processes rather than layering AI atop them.

Hospitals deploying AI successfully aren’t simply adding tools. They’re re-architecting:

• intake and scheduling

• triage and routing

• clinical documentation

• coding and billing

• authorization workflows

• care navigation

• discharge planning

For the first time, clinical operations teams are redesigning the connective tissue of care delivery — the administrative burden that costs the U.S. system $740B per year.

AI is not merely automating tasks; it is redefining the operating model of a healthcare system.

This is structurally different from the pharma environment, where regulatory inertia, siloed data, and long R&D cycles dampen the velocity of workflow reinvention.

The implications are profound:

• Healthcare operations may become the proving ground for generalizable AI agents.

• Biotech companies may eventually inherit agent-ready workflows from clinical settings.

• The first “AI-native healthcare systems” may emerge before the first “AI-native pharma.”

3. Multimodal AI Is Doing More Than Predicting: It Is Beginning to Interpret Biology

The 2025 npj Precision Oncology review on multimodal intelligence (MMAI) marks a turning point:
oncology is becoming the first clinical domain where AI can integrate the full patient phenotype.

Instead of analyzing single data streams — CT scans, WSI pathology slides, genomics, or clinical notes — MMAI models such as MUSK, TRIDENT, and ABACO learn across modalities, revealing patterns inaccessible to traditional pipelines.

Examples include:

• MUSK inferring melanoma relapse risk by combining histopathology, metadata, and genomic features

• TRIDENT improving NSCLC immunotherapy stratification by fusing radiomics, pathology morphology, and mutation states

• ABACO using real-world evidence to create continuously updating cross-cohort signatures

What is striking is not just performance — but mechanistic plausibility.
These models don’t merely forecast; they capture relationships across modalities that reflect underlying tumor biology, therapeutic response, and disease progression.

This is a qualitatively different kind of AI:

not prediction as pattern-matching, but prediction as biological hypothesis generation.

Multimodal intelligence may become the first AI capability that meaningfully improves patient stratification, trial enrichment, and therapeutic decision-making at scale.

4. Agentic workflows and federated learning are beginning to reshape drug discovery itself

Marshall’s Nature Biotechnology article synthesizes what many in the field have observed anecdotally:
AI is no longer an adjunct to drug discovery — it is now embedded into the backbone of the R&D stack.

Three shifts stand out:

A. Foundation models are being trained on previously inaccessible industrial datasets

Lilly’s TuneLab provides a case study:
For the first time, decades of ADME, tox, PK, and developability data from big pharma are flowing into shared foundation models — without anyone giving up proprietary data.

TuneLab creates a federated learning network where:

• models move

• weights update

• data stay behind the firewall

This is transformative because it solves the most persistent barrier to ML in drug discovery:
pharma-grade data scarcity.

B. Agentic R&D loops are emerging in top-tier discovery engines

At places like Genentech, Nimbus, Relay, insitro, and PostEra, AI systems are increasingly able to:

• design compounds

• evaluate LOE (lines of evidence)

• perform in silico experiments

• select actual wet-lab assays

• trigger robotic execution

This moves AI from “decision support” to experimental orchestration.

In Marshall’s words, R&D agents are becoming:

“automated systems that reason, plan, and use tools to advance hypotheses through the wet lab.”

This mirrors trends in other fields (e.g., code-generation agents), but with implications that are scientifically and economically profound.

C. The geography of biotech innovation is fracturing — and flattening

The Insilico Abu Dhabi example — where four local scientists, supported by an automated multimodal computational stack, advance candidates toward clinical phases — is not an outlier.

It is a sign.

As models become stronger and lab automation more portable, the catalytic requirement of “being in Boston or San Francisco” weakens.

R&D becomes:

• more distributed

• more computational

• less capital-intensive

• less geographically anchored

The wet lab no longer defines the boundary of innovation capacity.

The compute infrastructure does.

5. Meanwhile, Evaluate shows the business architecture of biotech is undergoing its own reorganization

While AI reconfigures workflows, an Evaluate report shows that the business structure of biopharmaceutical innovation is realigning.

Three dynamics are especially important:

A. Biotech is becoming modular

Asset-centric structures, pipeline carve-outs, and platform-based drug creation have turned biotech into a collection of compact, high-velocity innovation modules.

B. Royalty financing and alternative capital are replacing traditional models

This allows small biotechs to extend runways without dilutive equity — aligning perfectly with AI-driven pipelines that require more compute and less wet lab spend.

C. Reformulation and delivery innovation are back in vogue

Subcutaneous or oral alternatives to injectables, sustained-release systems, and consumer-facing formulations (especially in GLP-1s and biologics) are commanding high valuations.

This aligns with the broader theme:

Incremental but patient-centered innovation is now commercially and clinically meaningful.

6. The Emergence of an Innovation Commons

Across these domains — healthcare operations, oncology, R&D, and business architecture — a common pattern emerges.

Not centralization.
Not fragmentation.

But interconnection.

A new system is forming — not as a monolithic platform, but as a distributed intelligence layer that connects:

• multimodal clinical data

• federated R&D models

• operational AI in provider systems

• agentic discovery loops

• modular biotech financing

• flexible commercialization pathways

This is not a top-down transformation.
It is a bottom-up reconfiguration driven by hundreds of systems learning, integrating, and iterating in parallel.

Discovery no longer belongs to one geography.
Operational AI no longer belongs to one vendor.
Model innovation no longer belongs to one industry segment.

This is the innovation commons — diffuse, dynamic, and increasingly inclusive.

7. What Still Limits the System (and Why That Matters)

Despite its momentum, this new ecosystem faces critical constraints:

• biological data deserts (membrane proteins, mucus-barrier biology, highly reactive chemotypes)

• continued Phase 2 attrition despite improved candidate quality

• regulatory uncertainty around agentic systems and multimodal diagnostics

• workflow resistance in physician and clinical research communities

• the need for better evaluation frameworks and clinical interpretability

These challenges are not trivial, but they are no longer existential.
They are solvable through engineering, data generation, and coordinated governance.

This, in itself, is a profound shift.

8. The 2025 Answer

So, was there a greater bridge between the haves and have-nots over the past year?

Yes — but not as a single span.
The bridge is being built as a network:

• healthcare systems deploying AI-native operations

• oncology teams embracing multimodal clinical reasoning

• R&D organizations adopting agentic pipelines

• pharma entities opening model ecosystems

• biotechs adopting modular, capital-efficient structures

The moat in integrating AI isn’t data hoarding — it’s participation in model ecosystems.

Innovation is no longer gated by capital, geography, or legacy infrastructure.
It is gated by the ability to integrate, collaborate, orchestrate, and participate.

This is the new innovation commons.
And for the first time in decades, it carries the genuine potential to narrow — rather than widen — the gap